SCHEMBL6598912

SCHEMBL6598912

O=CC=Cc1ccc(Cl)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.63
MAPT P10636 6/20 0.50
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
GAA P10253 2/20 0.50
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
POLB P06746 1/20 0.46
LMNA P02545 6/20 0.44
KMT2A Q03164 4/20 0.44
MAOB P27338 1/20 0.44
MEN1 O00255 3/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
PKM P14618 2/20 0.42
TTR P02766 1/20 0.42
PTPN5 P54829 1/20 0.42
ALPL P05186 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10515832 1.00 TDP1 (0.63) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL29405545 1.00 TDP1 (0.63) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL11454521 0.87 TDP1 (0.60) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL28908860 0.83 TDP1 (0.47) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL28908861 0.83 TDP1 (0.47) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL12402952 0.80 GABRA1 (0.45) TDP1MAPTALDH1A1KDM4ENPC1
SCHEMBL31074940 0.80 CDK4 (0.55) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL21676102 0.80 TDP1 (0.44) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL20292376 0.80 CDK4 (0.55) TDP1MAPTALDH1A1KDM4EL3MBTL1
SCHEMBL16599459 0.80 TDP1 (0.44) TDP1MAPTALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0279095-A1 Chemotherapeutic composition SHIKOKU CHEMICALS CORPORATION (JP) 1988-08-24 EP claimed
EP-0209843-A2 Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use KANEBO, LTD. (JP) 1987-01-28 EP claimed
CN-114105844-A Novel laccase inhibitor thiosemicarbazone compound and preparation method and application thereof 中国农业大学 2022-03-01 CN disclosed
EP-2739626-B1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INT BV (NL) 2016-05-04 EP disclosed
US-9096599-B2 Spiroindoline compounds INTERVET INC. (US) 2015-08-04 US disclosed
US-20140163056-A1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INC. 2014-06-12 US disclosed
EP-2739626-A1 NOVEL SPIROINDOLINE COMPOUNDS Intervet International B.V. (NL) 2014-06-11 EP disclosed
WO-2013017678-A1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INTERNATIONAL B.V. (NL) 2013-02-07 WO disclosed
EP-1458679-A2 PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2004-09-22 EP disclosed
WO-2003053923-A2 PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-07-03 WO disclosed
EP-0330132-A1 Azolylmethylcycloalkyloxiranes, their preparation and use as plant-protective agents BASF Aktiengesellschaft (DE) 1989-08-30 EP disclosed
US-4710513-A Substituted pyranone inhibitors of cholesterol synthesis MERCK & CO., INC. (US) 1987-12-01 US disclosed
EP-0209843-A2 Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use KANEBO, LTD. (JP) 1987-01-28 EP disclosed
US-4567289-A ANTICHOLESTEROL ANTILIPEMIC MERCK & CO., INC. (US) 1986-01-28 US disclosed
US-4459422-A Substituted pyranone inhibitors of cholesterol synthesis MERCK & CO., INC. (US) 1984-07-10 US disclosed
US-4448710-A Corrosion inhibitors including a 3-dialkylamino-3-phenylethenylprop-1-yne GAF CORPORATION (US) 1984-05-15 US disclosed
EP-0080794-A1 Corrosion inhibitors containing N,N,1-trisubstituted prop-2-ynyl amines GAF CORPORATION (US) 1983-06-08 EP disclosed
US-4375475-A ANTICHOLESTEROL AGENTS MERCK & CO., INC. (US) 1983-03-01 US disclosed
EP-0024348-A1 Substituted 6-Phenethyl-and phenylethenyl-3,4,5,6-tetrahydro-4-hydroxytetraydropyran-2-ones in the4-R trans stereoisomeric forms and the corresponding dihydroxy acids, process for preparing and pharmaceutical composition comprising them MERCK & CO. INC. (US) 1981-03-04 EP disclosed
US-4087549-A Sulphonic acid containing indenyl derivatives MERCK & CO., INC. (US) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163056-A1 NOVEL SPIROINDOLINE COMPOUNDS PKD2, PKD1, REN TDP1 4688/4885MAPT 3915/4885ALDH1A1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.